Department of Clinical Chemistry, Microbiology and Immunology; Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
PLoS One. 2013;8(4):e60275. doi: 10.1371/journal.pone.0060275. Epub 2013 Apr 1.
Chronic lymphocytic leukemia (CLL) is a disease with variable clinical outcome. Several prognostic factors such as the immunoglobulin heavy chain variable genes (IGHV) mutation status are linked to the B-cell receptor (BCR) complex, supporting a role for triggering the BCR in vivo in the pathogenesis. The miRNA profile upon stimulation and correlation with IGHV mutation status is however unknown. To evaluate the transcriptional response of peripheral blood CLL cells upon BCR stimulation in vitro, miRNA and mRNA expression was measured using hybridization arrays and qPCR. We found both IGHV mutated and unmutated CLL cells to respond with increased expression of MYC and other genes associated with BCR activation, and a phenotype of cell cycle progression. Genome-wide expression studies showed hsa-miR-132-3p/hsa-miR-212 miRNA cluster induction associated with a set of downregulated genes, enriched for genes modulated by BCR activation and amplified by Myc. We conclude that BCR triggering of CLL cells induces a transcriptional response of genes associated with BCR activation, enhanced cell cycle entry and progression and suggest that part of the transcriptional profiles linked to IGHV mutation status observed in isolated peripheral blood are not cell intrinsic but rather secondary to in vivo BCR stimulation.
慢性淋巴细胞白血病(CLL)是一种临床表现各异的疾病。几种预后因素,如免疫球蛋白重链可变基因(IGHV)突变状态,与 B 细胞受体(BCR)复合物有关,支持触发体内 BCR 在发病机制中的作用。然而,刺激后的 miRNA 谱及其与 IGHV 突变状态的相关性尚不清楚。为了评估体外 BCR 刺激对外周血 CLL 细胞的转录反应,我们使用杂交阵列和 qPCR 测量了 miRNA 和 mRNA 的表达。我们发现 IGHV 突变和未突变的 CLL 细胞都以 MYC 和其他与 BCR 激活相关的基因的表达增加以及细胞周期进展的表型做出反应。全基因组表达研究表明,hsa-miR-132-3p/hsa-miR-212 miRNA 簇诱导与一组下调基因相关,这些基因富含受 BCR 激活调节并被 Myc 扩增的基因。我们得出结论,BCR 触发 CLL 细胞诱导与 BCR 激活相关的基因的转录反应,增强细胞周期进入和进展,并表明与在分离的外周血中观察到的 IGHV 突变状态相关的部分转录谱不是细胞内在的,而是继发于体内 BCR 刺激。